RxDoctor Payments Data

Roger Wells, PA

Physician Assistant · Lexington, NENPI 1508842469

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 82 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$318
  • AbbVie$283
  • Novo Nordisk$181
  • Lilly USA, LLC$165
  • Johnson & Johnson$64
  • Amgen$49
  • plus $420 from 20 others

What the payments were for

  • Food & beverage$1,479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,479 in reported general payments places this provider in the 75th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$3,544
Medicare patients
27
Services billed
51

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$62,578
OzempicSemaglutide53$59,910
TrulicityDulaglutide47$51,079
FarxigaDapagliflozin Propanediol57$43,400
JardianceEmpagliflozin44$38,954
MounjaroTirzepatide23$23,382
RybelsusSemaglutide11$22,084
MyrbetriqMirabegron12$9,085
VraylarCariprazine Hcl13$9,025
Synjardy XrEmpagliflozin/Metformin Hcl16$8,889
XareltoRivaroxaban16$8,780
AbrysvoRsv Vacc, Pref A And Pref B/Pf26$8,392
Atorvastatin Calcium264$4,654
SymbicortBudesonide/Formoterol Fumarate12$2,615
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$181$81,99364 claims
Lilly USA, LLCTrulicity, Mounjaro$165$74,46170 claims
AstraZenecaFarxiga, Symbicort$318$46,01569 claims
Astellas Pharma US IncMyrbetriq$45$9,08512 claims
AbbVieVraylar$283$9,02513 claims
Johnson & JohnsonXarelto$64$8,78016 claims
GSKShingrix$24$2,49111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lexington

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →